FIPB refers Gland Pharma proposal to CCEA for approval
NEW DELHI: Inter-ministerial body FIPB has recommended the Rs 4,315-crore foreign investment proposal of Gland Pharma Limited to the Cabinet Committee on Economic Affairs (CCEA) for approval.
The Foreign Investment Promotion Board (FIPB) has deferred a decision on FDI proposals of Vodafone Mobile Services, the finance ministry said in a statement.
The board approved six FDI proposals involving inflows of Rs 84.69 crore and rejected five proposals.
Gland Pharma Limited, a brownfield pharmaceutical Indian company, is seeking approval for its initial acquisition of up to 86.08 per cent by Shanghai Fosun Pharmaceutical (Group) Company Limited, a public listed company incorporated in China, the ministry said in a release.
The Chinese firm seeks to acquire stake in Gland Pharma through its subsidiaries outside India namely Fosun Pharma Industrial Ltd, Fosun Industrial Co Limited, Ample Up Limited, Lustrous Star Limited and Regal Gesture Limited.
"Subsequently, Fosun also has the contractual right to acquire 100 per cent shares of Gland Pharma from other shareholders of the company in one or more tranches," it added.
The proposal of Gland Pharma has been recommended for approval of Cabinet Committee on Economic Affairs (CCEA), the ministry said. The proposal entails FDI worth Rs 4,315 crore.
The proposals approved by the FIPB include a Rs 65-crore PMC Group International's proposal and Crown Cement Manufacturing India Pvt Ltd's for Rs 15.51 crore investment.
The release further said Vodafone Mobile Services Ltd,a 100 per cent foreign owned Indian company has sought post- facto approval for the scheme of amalgamation among Vodafone Mobile Services Limited, Vodafone Digilink Limited, Vodafone South Limited, Vodafone East Limited and Vodafone Cellular Limited.
However, the Board headed by Economic Affairs Secretary Shaktikanta Das deferred decision on the application.
The other proposals on which decision was deferred include investment proposals of Sistema Shyam TeleServices Limited, Datawind Innovations Private Limited, HSBC Securities and Capital Markets (India) Private Limited and G4S Secure Solutions (India) Private Limited.
Investment applications of PERI India Pvt Ltd, Limpkin Telecom Private Limited, LS Cable India Private Limited, Maxaim Network Private Limited, and Xerox India Limited have been rejected, the release said.
The Foreign Investment Promotion Board (FIPB) has deferred a decision on FDI proposals of Vodafone Mobile Services, the finance ministry said in a statement.
The board approved six FDI proposals involving inflows of Rs 84.69 crore and rejected five proposals.
Gland Pharma Limited, a brownfield pharmaceutical Indian company, is seeking approval for its initial acquisition of up to 86.08 per cent by Shanghai Fosun Pharmaceutical (Group) Company Limited, a public listed company incorporated in China, the ministry said in a release.
The Chinese firm seeks to acquire stake in Gland Pharma through its subsidiaries outside India namely Fosun Pharma Industrial Ltd, Fosun Industrial Co Limited, Ample Up Limited, Lustrous Star Limited and Regal Gesture Limited.
"Subsequently, Fosun also has the contractual right to acquire 100 per cent shares of Gland Pharma from other shareholders of the company in one or more tranches," it added.
The proposal of Gland Pharma has been recommended for approval of Cabinet Committee on Economic Affairs (CCEA), the ministry said. The proposal entails FDI worth Rs 4,315 crore.
The proposals approved by the FIPB include a Rs 65-crore PMC Group International's proposal and Crown Cement Manufacturing India Pvt Ltd's for Rs 15.51 crore investment.
The release further said Vodafone Mobile Services Ltd,a 100 per cent foreign owned Indian company has sought post- facto approval for the scheme of amalgamation among Vodafone Mobile Services Limited, Vodafone Digilink Limited, Vodafone South Limited, Vodafone East Limited and Vodafone Cellular Limited.
However, the Board headed by Economic Affairs Secretary Shaktikanta Das deferred decision on the application.
The other proposals on which decision was deferred include investment proposals of Sistema Shyam TeleServices Limited, Datawind Innovations Private Limited, HSBC Securities and Capital Markets (India) Private Limited and G4S Secure Solutions (India) Private Limited.
Investment applications of PERI India Pvt Ltd, Limpkin Telecom Private Limited, LS Cable India Private Limited, Maxaim Network Private Limited, and Xerox India Limited have been rejected, the release said.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd